that consists of VEGF-C (8, 9) and VEGF-D (10) (also known as "c-Fos-induced growth factor" or FIGF (11) ). These two growth factors are structurally and functionally related, because they are the only human VEGFs that bind both of the cell surface receptor tyrosine kinases VEGFR-2 (KDR/Flk1) and VEGFR-3 (Flt4) (8, 10 ) that signal for angiogenesis and lymphangiogenesis, respectively (12) (13) (14) . Furthermore, they are the only VEGFs initially synthesized as precursor proteins containing long N-and C-terminal propeptides (8, 10) in addition to a central receptor-binding domain known as the VEGF homology domain (VHD) (10) . In contrast to human VEGF-D, the mouse homologue is specific for mouse VEGFR-3; it does not bind mouse VEGFR-2 (15) . VEGF-D may play a role in embryonic development and tumor biology as it is angiogenic (16), lymphangiogenic (12) , expressed in vascular smooth muscle and human tumors (17, 18) , and promotes endothelial cell survival (19) and metastatic spread of tumor cells via lymphatic vessels (20) .
Studies of the proteolytic processing of human VEGF-D demonstrated that it exists in numerous forms in the extracellular milieu, both in vivo and in vitro. Some VEGF-D molecules are completely processed (i.e. with both the N-and C-terminal propeptides cleaved from the VHD), whereas others are partially processed (i.e. with either propeptide still attached to the VHD) or remain unprocessed (21) . Proteolysis is important for receptor binding as fully processed mature human VEGF-D binds both VEGFR-2 and VEGFR-3 with much greater affinity than does the unprocessed form (21) .
The C-terminal propeptide of VEGF-D is cysteine-rich; the location of many of the cysteine residues resembles the spacing of the repeat units found in the Balbiani ring 3 protein (BR3P), a protein synthesized in the salivary glands of the midge Chironomus tentans and which is thought to be involved in the process of forming larval silk (22, 23) . It has been proposed that the C-terminal propeptide of VEGF-C, which is highly homologous to VEGF-D and contains BR3P repeats, folds into an independent structural domain that may be involved in establishing a supramolecular structure that regulates the availability of these growth factors in tissues (8) .
Recent studies of the receptor-binding specificity of the mature form of mouse VEGF-D revealed an unexpected difference from the human homologue, as the mouse protein did not bind mouse VEGFR-2 (15) . Little is known about the structure, proteolytic processing, and biological function of mouse VEGF-D, although it is known to be angiogenic in the rabbit cornea model (16) .
Here, we report that alternative RNA splicing generates two different isoforms of mouse VEGF-D protein with distinct Cterminal propeptides. Both isoforms were expressed in all of the adult mouse tissues and at all of the stages of embryonic development that were analyzed. The pattern of proteolytic processing of both mouse VEGF-D isoforms was similar to that of the human homologue. However, the two mouse isoforms were differentially glycosylated when expressed in cells capable of processing VEGF-D. This study demonstrates that RNA splicing, protein glycosylation, and proteolysis are mechanisms for generating diversity of mouse VEGF-D structure.
EXPERIMENTAL PROCEDURES
Isolation and Characterization of cDNA and Genomic Clones-Mouse VEGF-D cDNAs were isolated by hybridization screening (24) of an adult mouse lung cDNA library (Stratagene) using as a probe a human VEGF-D cDNA as reported previously (GenBank TM accession number AJ000185) (10) . Mouse VEGF-D cDNA, corresponding to base pairs 202-1447 of a previously reported mouse FIGF (VEGF-D) cDNA (GenBank TM accession number X99572) (11) , was used as a probe to isolate genomic clones from a FIX II library containing genomic DNA from mouse strain 129Sv/J (Stratagene). In addition, a bacterial artificial chromosome (BAC) library of 129Sv/J mouse genomic DNA (Genome Systems, Inc., St. Louis, MO) was screened by PCR using an oligonucleotide primer targeted to intron 1 (5Ј-ATCAGAATAACCTTAAC-TAGT) and an antisense primer (5Ј-TTTCAGTGTCATAGAAAGTT) targeted to intron 2. A single BAC clone was identified. The genomic organization and exon-intron boundaries of the mouse VEGF-D gene were determined by analysis of the lambda and BAC clones by restriction mapping, Southern hybridization with exon-specific oligonucleotides (24) , and DNA sequencing. One of the lambda clones, designated M18, contained exons 1 and 2. The other clone, designated M19, contained exons 6 and 7. The BAC clone identified by PCR contained exons 3-5.
Reverse Transcription-PCR (RT-PCR) Analysis of VEGF-D mRNA-Total RNA was prepared from 129Sv/ter mouse embryos and adult tissues using the guanidine thiocyanate method as described previously (25). To calculate the ages of embryos, the day of plugging was denoted as 0.5-days-old. All embryos were collected at the same time each day to ensure that the calculation of age was accurate. Reverse transcriptase reactions were carried out with random hexamer primers and 1 g of total RNA using a First Strand cDNA synthesis kit (Roche Molecular Biochemicals) according to the manufacturer. 5% of the resulting cDNA was used as template for each PCR. Transcripts encoding VEGF-D 358 and VEGF-D 326 were detected by PCR using different primer pairs. A 503-base pair PCR product derived from the VEGF-D 358 transcript was amplified with a sense primer specific to exon 5, VD358F (5Ј-GTCCTCATTCCAAGAAACTC), and an antisense primer specific to exon 7, VD358R (5Ј-GGTAGTGGGCAACAGTGA-CAG), whereas a 732-base pair product derived from the VEGF-D 326 transcript was amplified with a sense primer specific to exon 3, VD326F (5Ј-GAAGAATGGCAGAGGACCCAA), and an antisense primer specific to exon 6, VD326R (5Ј-GTGCTTGGACTCTGAGAGAAAAG). For locations of primers in VEGF-D transcripts, see Fig. 3D . PCR was carried out using AmpliTaq Gold TM DNA polymerase (Applied Biosystems, Foster City, CA) under the following conditions: denaturation at 95°C for 10 min followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s with this temperature decreasing by 0.5°C/ cycle, and extension at 72°C for 30 s. This profile was followed by 25 cycles of denaturation at 95°C for 30 s, annealing at 50°C for 30 s, and extension at 72°C for 30 s. All reactions concluded with a final 7-min extension at 72°C. PCR products were detected by ethidium bromide staining, and their identities were confirmed by Southern hybridization (24) with oligonucleotides specific for the central region of each product. The oligonucleotide specific for the VEGF-D 358 PCR product (Oligo358, 5Ј-CAGATGTCCTTTTCACACCAG) was derived from exon 7 of the VEGF-D gene, whereas the oligonucleotide specific for the VEGF-D 326 product (Oligo326, 5Ј-GTCAATGGTCTTTTCGCTTTCC) was derived from exon 6 (see Fig. 3D ). Glyceraldehyde-3-phosphate dehydrogenasecontrol PCR reactions were performed for all samples to confirm the integrity of the RNA used in the cDNA synthesis reaction.
Expression Vectors-VEGF-D 358 and VEGF-D 326 were expressed in 293EBNA cells using the vector pEFBOS-SS-Myc-FLAG (see Fig. 4A ) that is a derivative of pEFBOS-SS-FLAG (a kind gift from Claire McFarlane, The Walter and Eliza Hall Institute, Melbourne, Australia) used to tag proteins with two Myc epitopes at their N termini and a single FLAG epitope at their C termini. For the VEGF-D 358 expression construct, DNA encoding Arg (23) to Pro (358) of VEGF-D 358 was amplified by PCR using a sense primer (5Ј-AGCTACGCGTAGCGAACAT-GGACCAGTGAAG) and an antisense primer (5Ј-AGCTGGCGCGCCG-GGTTCTCCTGGCTGTAGAGTCC) and a mouse VEGF-D 358 cDNA.
The PCR product was digested with AscI and MluI and inserted into the AscI site of pEFBOS-SS-Myc-FLAG to generate pEFBOS-SS-Myc-VEGF-D 358 -FLAG (Fig. 4A) . For the VEGF-D 326 expression construct, a DNA fragment encoding Arg (23) to Pro (326) of VEGF-D 326 was amplified by PCR using a sense primer (5Ј-AGC TGG CGC GCC GCA GCG AAC ATG GAC CAG TGA AGG) and an antisense primer (5Ј-AGC TGG CGC GCC GGG GAA AGC GAA AAG ACC ATT GA). The PCR product was inserted into the unique AscI site of pEFBOS-SS-Myc-FLAG to generate the plasmid designated as pEFBOS-SS-Myc-VEGF-D 326 -FLAG (Fig. 4A) .
Protein Expression and Purification-293EBNA cells were transiently transfected with purified expression vectors using FuGene6 transfection reagent according to the manufacturer (Roche Molecular Biochemicals). Derivatives of VEGF-D 358 and VEGF-D 326 , tagged with the FLAG octapeptide, were purified from conditioned medium by anti-FLAG (M2) affinity chromatography as described previously (21) .
Protein Quantitation-The extinction coefficients of proteins were estimated based on amino acid composition using the ProtParam tool program at the ExPASy website (www.expasy.com). Proteins were quantitated by spectrophotometry at 280 nm. The relative abundance of each protein was confirmed by SDS-PAGE followed by silver staining of serial dilutions of these proteins.
SDS-PAGE and Western Blotting-Proteins were fractionated by SDS-PAGE under reducing conditions as described previously (24) . For Western blotting, proteins were transferred to Immobilon P membrane (Millipore, Bedford, MA). Membranes were blocked, washed, incubated with horseradish peroxidase-conjugated anti-FLAG antibody (clone M2, Sigma), as described by the manufacturers, and detection was by ECL (Pierce). For detection of the VHD or Myc epitopes, membranes were analyzed using biotinylated affinity-purified antiserum (VHD antibody, R&D Systems, Minneapolis, MN) raised against amino acids 98 -206 of mouse VEGF-D, which corresponds to the VHD, and streptavidinhorseradish peroxidase conjugate (Roche Molecular Biochemicals, Indianapolis, IN) or anti-Myc antibody (clone 9E10, Zymed Laboratories Inc., San Francisco, CA) and horseradish peroxidase-conjugated goat anti-mouse antibody (Bio-Rad) as described by the manufacturers.
N-terminal Amino Acid Sequencing-N-terminal amino acid sequences were determined using a Hewlett-Packard biphasic N-terminal protein sequencer (Model G1005A, Hewlett-Packard, Palo Alto, CA). Samples blotted onto membrane were either loaded directly in the membrane-compatible sequencing column or onto the hydrophobic half of the biphasic sequencer column (without desalting) using the pressure-driven sample applicator (previously equilibrated with 2% (v/v) trifluoroacetic acid) by first diluting the sample into 1 ml of 2% (v/v) trifluoroacetic acid and applying it under nitrogen pressure (40 p.s.i.). Sequence cycles were performed automatically using the Routine 3.0 program employing ethyl acetate chemistry. Amino acids from each cycle were determined and quantitated by their respective elution upon reversed-phase liquid chromatography.
Endoglycosidase F Treatment-VEGF-D 358 and VEGF-D 326 (500 ng) were denatured in 5% SDS/phosphate-buffered saline for 3 min at 100°C in a reaction volume of 10 l. Proteins were cooled on ice, added to a 90-l solution containing 250 mM NaOAc, 20 mM EDTA, pH 8.0, 10 mM ␤-mercaptoethanol, 10 mg/ml Triton X-100, and 0.36 units of endoglycosidase F (Roche Molecular Biochemicals), and incubated for 18 h at 37°C. As a control, endoglycosidase F was omitted from duplicate protein samples and replaced with H 2 O. Proteins were then analyzed by SDS-PAGE and Western blotting with anti-FLAG antibody.
Bioassays of Mouse VEGFR-2 and Human VEGFR-3 Binding and
Cross-linking-Bioassays for monitoring the binding and crosslinking of VEGFR-2 and VEGFR-3 involved the use of cell lines expressing chimeric receptors consisting of the extracellular ligandbinding domain of mouse VEGFR-2 or human VEGFR-3 and the transmembrane and cytoplasmic domains of the mouse erythropoietin receptor (EpoR). The chimeric receptors had been transfected into the Ba/F3 cell line, a pre-B cell line that survives and proliferates in the presence of interleukin-3 (IL-3) but which dies after IL-3 deprivation. It has been shown previously that signaling from the cytoplasmic EpoR domain of chimeric receptors upon ligand binding is capable of rescuing these cells in the absence of IL-3 (26) . The expression of the VEGFR-2/EpoR and VEGFR-3/EpoR chimeric receptors in Ba/F3 cells allows detection of specific ligand binding and cross-linking of the extracellular domains of these receptors that result in signaling from the cytoplasmic domain of the EpoR and cell survival and proliferation in the absence of IL-3. The cell lines expressing the chimeric receptors are designated VEGFR-2-EpoRBa/F3 (10, 27) and VEGFR-3-EpoR-Ba/F3 (28) . Samples of VEGF-D were diluted in cell culture medium (Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine serum, 50 mM L-glutamine, 50 g/ml gentamicin, 1.2 mg/ml G418) deficient in IL-3. Bioassay cell lines were incubated in the medium for 48 h at 37°C, and DNA synthesis was then quantitated by the addition of 1 Ci of [ 3 H]thymidine and further incubation for 4 h prior to harvesting using an automated cell harvester (Tomtec, Orange, CT). Incorporated [ 3 H]thymidine was measured by ␤-counting (Canberra Packard "Top Count NXT™" scintillation counter, Meriden, CT). (Fig. 1A ) (22, 23) . In addition, the distinct region of VEGF-D 358 also contains two cysteine residues, which are not part of a BR3P-like motif. In contrast, the C-terminal region specific to VEGF-D 326 (residues 318 -326 of the VEGF-D 326 sequence) lacks cysteine residues and contains only nine amino acids.
RESULTS

Identification of Two
Analysis of the Expression of VEGF-D 358
and VEGF-D 326 -As cDNA libraries always contain a range of cDNAs with anomalous structures because of cloning artifacts, the existence of the two distinct transcripts encoding VEGF-D 358 and VEGF-D 326 was investigated further by RT-PCR using oligonucleotide primer pairs specific for each transcript (see "Experimental Procedures") and RNA from the lungs of embryonic day 15.5 mouse embryos, a tissue known to express the VEGF-D gene (21) . DNA fragments of the expected sizes were amplified from both transcripts, and the identities of the PCR products were confirmed by Southern blotting analysis with oligonucleotides specific for each PCR fragment (Fig. 1B ).
RT-PCR was then used to investigate the expression patterns of VEGF-D 358 and VEGF-D 326 during mouse embryonic development and in adult mouse tissues (Fig. 2) . Transcripts for both isoforms were detected at all time-points studied between days 9.5 and 17.5 of embryonic development and in all of the adult tissues investigated.
Structure of the Mouse VEGF-D Gene-The transcripts encoding VEGF-D 358 and VEGF-D 326 do not arise from different genes as Southern hybridization analysis of genomic DNA from W9.5 and 129Sv/ter mouse strains using four different restriction enzymes and probes to the 5Ј and 3Ј regions of the mouse VEGF-D gene detected a single band in each case (data not shown). This indicated that there is only one copy of the VEGF-D gene in the mouse genome. This finding is consistent with the mapping of the mouse VEGF-D gene by interspecific backcross analysis to a single location at the distal end of the mouse X chromosome (29) .
The structure of the mouse VEGF-D gene was characterized to determine the mechanism of splicing, which gives rise to the transcripts for VEGF-D 358 and VEGF-D 326 . The mouse VEGF-D gene spans at least 28.5 kilobases and consists of 7 exons (Fig. 3A) . The putative signal sequence for protein secre- . RTϩ denotes the product of PCR using mouse embryonic lung cDNA as template. RNAϪ denotes product from PCR using template from a reverse transcription reaction in which RNA was omitted. PCRϪ denotes product from PCR in which cDNA template was omitted.
tion identified by alignment with human VEGF-D (10) and the first nine residues of the N-terminal propeptide are encoded by exon 1. The VHD is encoded by sequences within exons 2-4, as is the case for the mouse VEGF-C gene. The C-terminal propeptide is encoded by the 3Ј region of exon 4 and by exons 5-7. All exon-intron boundaries conform to the consensus splice donor and acceptor sequences (30) and are well conserved with those in the VEGF-C gene (31) (Fig. 3B) .
The mechanism by which the transcripts for VEGF-D 358 and VEGF-D 326 are generated can be explained by the structure of exon 6. As shown in Fig. 3C , the VEGF-D 358 transcript is generated by a splice event from within exon 6 to the beginning of exon 7. A consensus splice donor site is located at the point at which this splice event occurs. In contrast, the transcript for VEGF-D 326 arises when this splice event does not occur. Therefore, the 3Ј region of exon 6 is represented in the VEGF-D 326 transcript but not in the VEGF-D 358 transcript (Fig. 3D) and at the C terminus with FLAG (Fig. 4A) were expressed and purified as described under "Experimental Procedures." Previous studies of human VEGF-D indicated that it is initially synthesized as a full-length protein (i.e. containing the VHD and both propeptides), which forms homodimers that are associated in an anti-parallel configuration with non-covalent interactions between the VHDs and possibly by disulfide bonding between the N-and C-terminal propeptides of each subunit of the dimer (Fig. 4B) (21) . Therefore, purification of human VEGF-D, based on affinity chromatography-targeting epitope tags at the N or C termini of the full-length form, gives rise to a mixture of polypeptides including unprocessed material, a range of partially processed derivatives, the free propeptides, and the VHD that has been cleaved from the propeptides (21) . The analysis of mouse VEGF-D 358 and VEGF-D 326 , expressed in 293EBNA cells and purified by anti-FLAG affinity chromatography from conditioned medium, revealed that in broad terms proteolytic processing was similar to that for human VEGF-D. Full-length VEGF-D 358 (detected by silver stain and Western blotting for Myc, VHD, and FLAG) was ϳ58 kDa (the same size as full-length human VEGF-D) and is larger than full-length VEGF-D 326 , which migrates as a ϳ55-kDa species under reducing conditions (Fig. 4C) . Such a size difference between the two mouse protein isoforms was expected because of their distinct C termini.
A ϳ36-kDa protein species was present in both the VEGF-D 358 and VEGF-D 326 preparations as detected by silver staining (Fig. 4C) . Western blot analysis indicated that this protein was a partially processed derivative of VEGF-D, consisting of the N-terminal propeptide and the VHD, as it was of the expected size based on the migration of the corresponding human VEGF-D derivative (21) and was detected using Myc and VHD antibodies (Fig. 4C) . Anti-FLAG antibody also detected a ϳ36-kDa polypeptide in the VEGF-D 358 material but not among the VEGF-D 326 polypeptides (Fig. 4C) . This polypeptide is the C-terminal propeptide of VEGF-D 358 that co-migrates with the N-terminal propeptide/VHD derivative. In addition, a very small quantity of a ϳ35-kDa protein species was also detected by silver stain and anti-FLAG antibody in the VEGF-D 358 lane (Fig. 4C) , which could be a form of the Cterminal propeptide that is differently glycosylated, because it was not detected with anti-Myc antibody even after prolonged exposure of autoradiographic film (data not shown), and there is indeed one potential N-linked glycosylation site in the Cterminal propeptide (10) . In contrast, anti-FLAG antibody detected two abundant polypeptides migrating at ϳ34 kDa and ϳ31 kDa in the VEGF-D 326 lane. These polypeptides were not detected using the Myc or VHD antibodies, indicating that they were two abundant forms of the C-terminal propeptide of VEGF-D 326 . A polypeptide of ϳ21 kDa, corresponding to the fully processed form consisting only of the VHD (21), was detected with VHD antibodies in preparations of both VEGF-D 358 and VEGF-D 326 (Fig. 4C) . VHD antibodies also detected bands of ϳ48 and ϳ45 kDa in VEGF-D 358 and VEGF-D 326 samples, respectively, corresponding to partially processed forms consisting of the VHD and the C-terminal propeptide.
To determine whether the ϳ34-and ϳ31-kDa VEGF-D 326 polypeptides were alternative forms of the C-terminal propeptide generated by proteolytic cleavage from the VHD at different sites, the N-terminal amino sequences of these derivatives were determined and found to be the same (Fig. 4D) . The sequence for both polypeptides, SIQTPEEDE, is identical to the N-terminal amino acid sequence of the C-terminal propeptide of human VEGF-D (21) A and B) . RNAϪ denotes product from PCR using template from a reverse transcription reaction in which RNA was omitted. PCRϪ denotes product from PCR in which cDNA was omitted.
acid sequence of the ϳ36-kDa protein species was also determined. It was ASISAREQKLISEEDLEQKL, which corresponds to the amino acids introduced by DNA cloning and the first and part of the second Myc-tags. This finding indicates, as expected, that this polypeptide is a partially processed derivative of VEGF-D 326 consisting of the Myc-tagged N-terminal propeptide and the VHD (Fig. 4D) , which is consistent with Western blot analysis.
VEGF-D 358 and VEGF-D 326
Are Differently Glycosylated-As the VEGF-D 326 C-terminal propeptides, which migrated at ϳ34 and ϳ31 kDa in reducing SDS-PAGE, did not arise by alternative use of a proteolytic cleavage site at their N termini, the possibility that they were differentially glycosylated was investigated. The C-terminal propeptides of VEGF-D 358 and VEGF-D 326 all contain a potential N-linked glycosylation site at positions 292-294 (numbered from the initiation methionine) (see Fig. 3A ) (10) . Carbohydrate moieties were removed using endoglycosidase F, and the C-terminal propeptides were analyzed by Western blotting with anti-FLAG antibody (Fig. 4E) . The ϳ36-kDa form and the much less abundant ϳ35-kDa form of the VEGF-D 358 C-terminal propeptide comigrated at ϳ35 kDa following endoglycosidase F treatment, indicating that this propeptide predominantly exists as a glycosylated form and that only a small fraction (the ϳ35-kDa form) remains unglycosylated or less glycosylated when expressed in 293EBNA cells. The two abundant forms of the VEGF-D 326 C-terminal propeptide, ϳ34 and ϳ31 kDa, co-migrated as a species of ϳ31 kDa following endoglycosidase F All splice donor and acceptor sites are indicated. The splice donor site shown for exon 6 is the same as for the splicing event, which gives rise to VEGF-D 358 . C, schematic representation of splicing events. Boxes represent exons (gray areas denoting coding regions and white areas denoting untranslated regions). The length of the untranslated region of exon 6 is unknown, whereas that for exon 7 is 516 bp. Introns are represented by thin horizontal lines, and arrows represent splicing events or direct read-through. The transcript for VEGF-D 358 is generated because of splicing from exon 6 to the beginning of exon 7, whereas that for VEGF-D 326 arises because this splice event does not occur. D, schematic representation of the transcripts for the mouse VEGF-D 358 and VEGF-D 326 isoforms. The transcripts for both isoforms contain a sequence derived from exon 1 to the splice acceptor site of exon 6. However, the VEGF-D 358 transcript lacks the sequence encoded by the 3Ј region of exon 6 and includes a sequence derived from exon 7, whereas VEGF-D 326 contains a sequence derived from the entire coding region and untranslated region of exon 6. The positions of the primer pairs (VD358F and VD358R, VD326F and VD326R) and oligonucleotides (Oligo-358 and Oligo-326) used to specifically amplify and identify PCR products derived from the VEGF-D 358 and VEGF-D 326 transcripts are shown, and the sizes of PCR products are indicated. Gray and white areas denote coding and untranslated regions, respectively. treatment (Fig. 4E) , indicating that they were differently glycosylated. This data and the N-terminal amino acid sequences indicated that the C-terminal propeptides of mouse VEGF-D were cleaved from the VHDs at the same site (homologous to the corresponding cleavage site in human VEGF-D (21)), but that differences in apparent molecular weight arose because of differential glycosylation. 326 -To compare the receptor interactions of VEGF-D 358 and VEGF-D 326 , these proteins were tested in the bioassays of VEGFR-2 and VEGFR-3 binding and crosslinking using cell lines VEGFR-2-EpoR-Ba/F3 and VEGFR-3-EpoR-Ba/F3 that express chimeric receptors comprised of the extracellular domains of mouse VEGFR-2 or human VEGFR-3 and the transmembrane and cytoplasmic domains of EpoR. In the absence of IL-3, these cells die unless they are provided with ligands that cross-link the chimeric receptors in which case signaling from the EpoR cytoplasmic domain drives cell survival and proliferation. As expected, VEGF-D 358 and VEGF-D 326 did not exhibit any activity in the VEGFR-2 bioassay (Fig.  5A) , which is consistent with previous findings indicating that mouse VEGF-D does not bind mouse VEGFR-2 (15). In contrast, VEGF-D 358 and VEGF-D 326 exhibited significant and similar activity in the VEGFR-3 bioassay (Fig. 5B) . DISCUSSION The expression of structurally distinct protein isoforms is a common mechanism in eukaryotes to generate proteins with (21) ). Arrows lead from the intracellular forms to the products of stepwise proteolytic processing that generate a mature form, which is a dimer of the VHD. Not all polypeptides become fully processed, therefore, unprocessed and partially processed forms are detected in cell culture supernatants (21) . Dimeric derivatives in which N-or C-terminal cleavage has occurred in only one subunit exist but for simplicity are not shown. All combinations of subunits with no processing or partial processing can be envisaged. related yet distinct structures, regulation, and function. Protein isoforms may be generated by the regulated expression of different genes of a multi-gene family or by the expression of distinct proteins from a single gene (32) . The VEGF family utilizes both of these mechanisms. Members of the VEGF family are encoded by different genes on different chromosomes (29, (33) (34) (35) . In addition, the generation of protein variants by alternative RNA splicing occurs among members of the VEGF family to generate protein diversity (36) . Typically, alternative splicing of RNA for members of the VEGF family produces protein isoforms with variation in the C-terminal regions of the proteins, which accounts for differences in heparin-binding affinity (1) . Differences in the affinities of the isoforms for heparin affects localization and bioavailability of the proteins (3, (37) (38) (39) (40) . Furthermore, splice variation influences receptor binding, e.g. differential binding to neuropilin-1 has been observed for different isoforms of VEGF, VEGF-B, and placenta growth factor (41) (42) (43) . Alternative splicing can therefore generate protein isoforms with different biochemical properties and functions.
Analysis of Receptor Binding and Cross-linking Induced by VEGF-D 358 and VEGF-D
Previous studies have shown that proteolytic processing is one mechanism to modulate the structure and receptor-binding properties of human VEGF-D (21) . Numerous forms of fully and partially processed human VEGF-D have been detected in vitro and in vivo (21) . The investigation described here indicates that mouse VEGF-D is proteolytically processed in a similar fashion to human VEGF-D. However, there is a further level of complexity of VEGF-D synthesis in mouse because of alternative splicing of RNA. This variation of RNA splicing generates two VEGF-D isoforms with distinct C-terminal propeptides. Although the distinct C-terminal propeptides of mouse VEGF-D are cleaved from the VHD to generate the mature form of the growth factor, they may be of functional significance because unprocessed and partially processed forms, in which the C-terminal propeptides have not been proteolytically cleaved from the VHD, are detected in vitro. In such unprocessed and partially processed forms, variation in the sequence of the C-terminal propeptide could act to vary protein localization, stability, folding, receptor binding, or susceptibility to proteolysis. Both VEGF-D isoforms are secreted from transiently transfected 293EBNA cells and can be immunoprecipitated from conditioned media, indicating that a proportion of both isoforms is freely soluble and not associated with the extracellular matrix laid down by these cells. However, it is not known whether any or what proportion of the secreted VEGF-D protein isoforms remains associated with the extracellular matrix. It is also possible that the free C-terminal propeptides (i.e. after dissociation from other VEGF-D polypeptides) have distinct biological functions, however, no such function has yet been reported.
Two abundant forms of the C-terminal propeptide of VEGF-D 326 are produced by 293EBNA cells that differ in their degree of glycosylation, whereas only one abundant form of the Cterminal propeptide of VEGF-D 358 is produced in this system. This result may be attributed to different folding of the mouse VEGF-D isoforms that could influence the access of glycosylation enzymes to the potential N-linked glycosylation site in the C-terminal propeptides. Glycosylation is another mechanism for increasing structural diversity of proteins and can affect cell-cell and cell-receptor interactions, protein folding, and stability (44) . However, variation in the C-terminal propeptides of the two mouse VEGF-D protein isoforms did not affect the capacity to bind and cross-link receptors, as the polypeptides derived from these isoforms exhibited the same activity in the VEGFR-2 and VEGFR-3 Ba/F3 bioassays of receptor binding and cross-linking.
The structures of the mouse VEGF-D and VEGF-C genes are highly conserved. Both genes contain the same number of exons, and the locations in the exons of the coding regions for the VHDs are the same (45) . The positions of all exon-intron boundaries with respect to the coding region are also conserved in both genes. However, the alternative splicing of VEGF-D RNA in a region corresponding to exon 6 of the gene has not been reported for the VEGF-C gene. The functional and structural similarities between the human VEGF-D and VEGF-C proteins have led to the classification of these two growth factors as a subfamily of the VEGF family (10) . The high degree of conservation of the structures of the VEGF-D and VEGF-C genes further confirms this classification and suggests that a gene duplication event during evolution may have generated the two genes. However, the function of both gene products has diverged since this hypothesized gene duplication event as mouse VEGF-C and VEGF-D display distinct receptor bind- used for these assays were generated from 293EBNA cells transfected with expression constructs encoding the full-length proteins and, hence, contained mixtures of full-length, partially processed, and fully processed material. Total protein content of these purified samples was estimated as described under "Experimental Procedures." ing specificities and have partially overlapping expression patterns (8 -10, 15, 46 -49) .
Further studies are required to determine the function of both the N-and C-terminal propeptides of mouse and human VEGF-D. These studies may reveal that differences in the amino acid sequence and glycosylation of the C-terminal propeptides affect protein localization by influencing interactions with extracellular matrix components as well as protein stability and function. Furthermore, these studies could investigate whether the variation in glycosylation of the C-terminal propeptides of VEGF-D 358 and VEGF-D 326 occurs in vivo and whether such variation is tissue-or organ-specific.
